1. Home
  2. Directory
  3. Connecticut
  4. Bridgeport
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1114998317

DR. STEVEN NEIL FRANKEL O.D.
Prescription History 1114998317
Optometrist in Bridgeport, CT

NPI Status: Active since January 27, 2006

Contact Information

192 FAIRFIELD AVE
BRIDGEPORT, CT
ZIP 06604
Phone: (203) 366-7504
Fax: (203) 366-5302

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEVEN NEIL FRANKEL O.D., an active Optometrist specialist practicing in Bridgeport, CT. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 318 documented patient claims. Among these therapy options, the most frequently utilized medication is Travoprost, which accounts for 89 claims alone.

Medication Index

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 24.4
Days Supply 712
CT State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills196.0
Peer Average Days Supply5,869
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.4% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $492.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.83

State Avg Cost Per Claim

$40.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 49
30-Day Fills 59.8
Days Supply 1,630
CT State Average Benchmarks
Peer Average Claims125.0
Peer Average 30-Day Fills242.5
Peer Average Days Supply6,977
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.8% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $493.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.06

State Avg Cost Per Claim

$28.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 32
30-Day Fills 41.5
Days Supply 1,115
CT State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills129.1
Peer Average Days Supply3,772
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,813.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$369.17

State Avg Cost Per Claim

$553.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 32.0
Days Supply 960
CT State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills98.0
Peer Average Days Supply2,902
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.2% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,354.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,176.55

State Avg Cost Per Claim

$1,318.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Optometry
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 438
CT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills56.2
Peer Average Days Supply1,649
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.3% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,549.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$221.86

State Avg Cost Per Claim

$276.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 27
30-Day Fills 56.1
Days Supply 1,680
CT State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills155.6
Peer Average Days Supply4,614
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.3% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $346.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.82

State Avg Cost Per Claim

$40.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Travoprost

Generic Formulation: TravoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 89
30-Day Fills 102.5
Days Supply 2,785
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills71.7
Peer Average Days Supply2,097
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 147.2% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,324.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$138.47

State Avg Cost Per Claim

$293.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Optometry
Provider Metrics Summary
Total Claims 49
30-Day Fills 51.0
Days Supply 1,340
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply1,704
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.1% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,862.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$282.90

State Avg Cost Per Claim

$504.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 22
30-Day Fills 28.5
Days Supply 855
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply1,647
Conservative Utilization

This provider writes prescriptions for this formulation 29.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,182.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$962.86

State Avg Cost Per Claim

$1,168.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEVEN NEIL FRANKEL O.D. provides transparency into local medical care patterns within Bridgeport, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.